JP2018519329A5 - - Google Patents

Download PDF

Info

Publication number: JP2018519329A5
Authority: JP; Japan
Prior art keywords: hydrogen; independently; compound; alkyl; compound according
Prior art date: 2016-07-06
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2017568208A

Other languages

English (en)

Japanese (ja)

Other versions

JP6882996B2 (ja

JP2018519329A (ja

Filing date

2016-07-06

Publication date

2019-07-25

2016-07-06 Application filed filed Critical

2016-07-06 Priority claimed from PCT/US2016/041160 external-priority patent/WO2017007832A1/en

2018-07-19 Publication of JP2018519329A publication Critical patent/JP2018519329A/ja

2019-07-25 Publication of JP2018519329A5 publication Critical patent/JP2018519329A5/ja

2021-01-07 Priority to JP2021001453A priority Critical patent/JP7410062B2/ja

2021-06-02 Application granted granted Critical

2021-06-02 Publication of JP6882996B2 publication Critical patent/JP6882996B2/ja

Status Active legal-status Critical Current

2036-07-06 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims description 165
229910052739 hydrogen Inorganic materials 0.000 claims description 116
239000001257 hydrogen Substances 0.000 claims description 116
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 86
125000000217 alkyl group Chemical group 0.000 claims description 74
150000002431 hydrogen Chemical class 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 27
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
208000035475 disorder Diseases 0.000 claims description 18
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 12
150000001413 amino acids Chemical class 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 10
208000014617 hemorrhoid Diseases 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
208000002193 Pain Diseases 0.000 claims description 6
208000028017 Psychotic disease Diseases 0.000 claims description 6
229930182558 Sterol Natural products 0.000 claims description 6
230000002496 gastric effect Effects 0.000 claims description 6
235000003702 sterols Nutrition 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
238000003786 synthesis reaction Methods 0.000 claims description 5
206010028980 Neoplasm Diseases 0.000 claims description 4
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
125000004452 carbocyclyl group Chemical group 0.000 claims description 4
229910052799 carbon Inorganic materials 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
210000003169 central nervous system Anatomy 0.000 claims description 4
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 4
206010015037 epilepsy Diseases 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
-1 methyl) Chemical compound 0.000 claims description 4
150000003432 sterols Chemical class 0.000 claims description 4
206010011878 Deafness Diseases 0.000 claims description 3
230000010370 hearing loss Effects 0.000 claims description 3
231100000888 hearing loss Toxicity 0.000 claims description 3
208000016354 hearing loss disease Diseases 0.000 claims description 3
208000024827 Alzheimer disease Diseases 0.000 claims description 2
206010002091 Anaesthesia Diseases 0.000 claims description 2
206010048946 Anal abscess Diseases 0.000 claims description 2
208000016583 Anus disease Diseases 0.000 claims description 2
208000019901 Anxiety disease Diseases 0.000 claims description 2
208000020925 Bipolar disease Diseases 0.000 claims description 2
208000014644 Brain disease Diseases 0.000 claims description 2
208000000094 Chronic Pain Diseases 0.000 claims description 2
206010009900 Colitis ulcerative Diseases 0.000 claims description 2
206010010774 Constipation Diseases 0.000 claims description 2
208000011231 Crohn disease Diseases 0.000 claims description 2
206010012289 Dementia Diseases 0.000 claims description 2
208000030814 Eating disease Diseases 0.000 claims description 2
208000032274 Encephalopathy Diseases 0.000 claims description 2
208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
208000023105 Huntington disease Diseases 0.000 claims description 2
208000019022 Mood disease Diseases 0.000 claims description 2
208000016285 Movement disease Diseases 0.000 claims description 2
208000029726 Neurodevelopmental disease Diseases 0.000 claims description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 2
208000018737 Parkinson disease Diseases 0.000 claims description 2
201000009916 Postpartum depression Diseases 0.000 claims description 2
208000006289 Rett Syndrome Diseases 0.000 claims description 2
206010039897 Sedation Diseases 0.000 claims description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
206010041250 Social phobia Diseases 0.000 claims description 2
208000006011 Stroke Diseases 0.000 claims description 2
206010042458 Suicidal ideation Diseases 0.000 claims description 2
208000009205 Tinnitus Diseases 0.000 claims description 2
208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
230000001154 acute effect Effects 0.000 claims description 2
208000005298 acute pain Diseases 0.000 claims description 2
230000006978 adaptation Effects 0.000 claims description 2
125000000539 amino acid group Chemical group 0.000 claims description 2
230000037005 anaesthesia Effects 0.000 claims description 2
208000029560 autism spectrum disease Diseases 0.000 claims description 2
208000010877 cognitive disease Diseases 0.000 claims description 2
206010009887 colitis Diseases 0.000 claims description 2
206010012601 diabetes mellitus Diseases 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
235000014632 disordered eating Nutrition 0.000 claims description 2
208000018459 dissociative disease Diseases 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
208000024732 dysthymic disease Diseases 0.000 claims description 2
206010014599 encephalitis Diseases 0.000 claims description 2
230000001037 epileptic effect Effects 0.000 claims description 2
208000007386 hepatic encephalopathy Diseases 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
230000001939 inductive effect Effects 0.000 claims description 2
206010022437 insomnia Diseases 0.000 claims description 2
201000006417 multiple sclerosis Diseases 0.000 claims description 2
230000035772 mutation Effects 0.000 claims description 2
208000030459 obsessive-compulsive personality disease Diseases 0.000 claims description 2
230000036407 pain Effects 0.000 claims description 2
208000022821 personality disease Diseases 0.000 claims description 2
208000014081 polyp of colon Diseases 0.000 claims description 2
208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
102000004169 proteins and genes Human genes 0.000 claims description 2
108090000623 proteins and genes Proteins 0.000 claims description 2
208000022610 schizoaffective disease Diseases 0.000 claims description 2
201000000980 schizophrenia Diseases 0.000 claims description 2
230000036280 sedation Effects 0.000 claims description 2
208000019116 sleep disease Diseases 0.000 claims description 2
125000002328 sterol group Chemical group 0.000 claims description 2
208000011117 substance-related disease Diseases 0.000 claims description 2
208000024891 symptom Diseases 0.000 claims description 2
231100000886 tinnitus Toxicity 0.000 claims description 2
230000009529 traumatic brain injury Effects 0.000 claims description 2
208000009999 tuberous sclerosis Diseases 0.000 claims description 2
230000000007 visual effect Effects 0.000 claims description 2
238000000034 method Methods 0.000 description 8
0 C[C@](CCC(*)(*)O*)[C@@](CC1)C(C)(CC2)[C@@]1[C@]1[C@]2C(C)(CC[C@](C2)O*)C2=CC1 Chemical compound C[C@](CCC(*)(*)O*)[C@@](CC1)C(C)(CC2)[C@@]1[C@]1[C@]2C(C)(CC[C@](C2)O*)C2=CC1 0.000 description 4
230000002265 prevention Effects 0.000 description 2
AWYRCQSXEMLVGF-MTBAOGSRSA-N CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O Chemical compound CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)C1[C@H]1C2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O AWYRCQSXEMLVGF-MTBAOGSRSA-N 0.000 description 1
GJRCVNWPDRRALB-NKDCYIQOSA-N CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)OC([C@H](C)N)=O)C2=CC1)OC([C@H](C)N)=O Chemical compound CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)OC([C@H](C)N)=O)C2=CC1)OC([C@H](C)N)=O GJRCVNWPDRRALB-NKDCYIQOSA-N 0.000 description 1
XGUXPCFYBZEUCL-XOLAWMNISA-N CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OS(O)(=O)=O Chemical compound CC(C)C(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OS(O)(=O)=O XGUXPCFYBZEUCL-XOLAWMNISA-N 0.000 description 1
JOYQWTTWWVZXLS-BTXZHLCBSA-N CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC([C@H](C(C)C)N)=O Chemical compound CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC([C@H](C(C)C)N)=O JOYQWTTWWVZXLS-BTXZHLCBSA-N 0.000 description 1
QODDHCYAHLEGKJ-MYFVGXIISA-N CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC([C@H](C)N)=O Chemical compound CC(C)[C@H](CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@H](C2)O)C2=CC1)OC([C@H](C)N)=O QODDHCYAHLEGKJ-MYFVGXIISA-N 0.000 description 1
NGIVIKXHOHDJHX-OETAEELFSA-N CCC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O Chemical compound CCC(CC[C@@H](C)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1)OC(CCC(O)=O)=O NGIVIKXHOHDJHX-OETAEELFSA-N 0.000 description 1
BLSDTZSARUNYKA-VGXOWKQNSA-N C[C@H](CCC(C)(C)OC(CCC(O)=O)=O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 Chemical compound C[C@H](CCC(C)(C)OC(CCC(O)=O)=O)[C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H]1[C@H]2[C@@](C)(CC[C@@](C)(C2)O)C2=CC1 BLSDTZSARUNYKA-VGXOWKQNSA-N 0.000 description 1
230000006735 deficit Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1

JP2017568208A 2015-07-06 2016-07-06 オキシステロールおよびそれらの使用の方法 Active JP6882996B2 (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP2021001453A JP7410062B2 (ja)	2015-07-06	2021-01-07	オキシステロールおよびそれらの使用の方法

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562189065P	2015-07-06	2015-07-06
US62/189,065		2015-07-06
PCT/US2016/041160 WO2017007832A1 (en)	2015-07-06	2016-07-06	Oxysterols and methods of use thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2021001453A Division JP7410062B2 (ja)	2015-07-06	2021-01-07	オキシステロールおよびそれらの使用の方法

Publications (3)

Publication Number	Publication Date
JP2018519329A JP2018519329A (ja)	2018-07-19
JP2018519329A5 true JP2018519329A5 (2)	2019-07-25
JP6882996B2 JP6882996B2 (ja)	2021-06-02

Family

ID=57686058

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
JP2017568208A Active JP6882996B2 (ja)	2015-07-06	2016-07-06	オキシステロールおよびそれらの使用の方法
JP2021001453A Active JP7410062B2 (ja)	2015-07-06	2021-01-07	オキシステロールおよびそれらの使用の方法
JP2022107293A Active JP7478190B2 (ja)	2015-07-06	2022-07-01	オキシステロールおよびそれらの使用の方法

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2021001453A Active JP7410062B2 (ja)	2015-07-06	2021-01-07	オキシステロールおよびそれらの使用の方法
JP2022107293A Active JP7478190B2 (ja)	2015-07-06	2022-07-01	オキシステロールおよびそれらの使用の方法

Country Status (8)

Country	Link
US (4)	US10696712B2 (2)
EP (2)	EP4316591A3 (2)
JP (3)	JP6882996B2 (2)
AU (2)	AU2016289965B2 (2)
CA (1)	CA2991311C (2)
HK (1)	HK1255500A1 (2)
MA (1)	MA42409A (2)
WO (1)	WO2017007832A1 (2)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20230747T1 (hr)	2011-09-08	2024-01-05	Sage Therapeutics, Inc.	Neuroaktivni steroidi, pripravci i njihova uporaba
SMT201800657T1 (it)	2013-03-13	2019-01-11	Sage Therapeutics Inc	Steroidi neuroattivi e loro metodi di utilizzo
WO2015195967A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
SG11201702799UA (en) *	2014-10-07	2017-05-30	Sage Therapeutics Inc	Neuroactive compounds and methods of use thereof
MX382122B (es) *	2015-07-06	2025-03-13	Sage Therapeutics Inc	Oxiesteroles y metodos de uso de los mismos.
PL3319611T3 (pl)	2015-07-06	2021-07-12	Sage Therapeutics, Inc.	Oksysterole i sposoby ich stosowania
AU2016289965B2 (en)	2015-07-06	2021-09-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
EP3436022B1 (en)	2016-04-01	2022-03-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10752653B2 (en)	2016-05-06	2020-08-25	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
WO2018009867A1 (en)	2016-07-07	2018-01-11	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
PT3519422T (pt)	2016-09-30	2022-12-05	Sage Therapeutics Inc	Oxisteróis substituídos em c7 e métodos como moduladores nmda
CA3041088C (en)	2016-10-18	2024-05-21	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
DK4105223T3 (da)	2016-10-18	2025-07-07	Sage Therapeutics Inc	Oxysteroler og fremgangsmåder til anvendelse deraf
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
CN110628737B (zh) *	2019-10-14	2022-06-07	南京农业大学	一个调控黄瓜矮化性状相关基因及其应用
IL308273A (en) *	2021-05-04	2024-01-01	Sage Therapeutics Inc	Neuroactive steroids for the treatment of mild cognitive impairment associated with Parkinson's disease
JP2024520805A (ja)	2021-06-11	2024-05-24	セージセラピューティクス，インコーポレイテッド	アルツハイマー病の治療のための神経活性ステロイド
WO2023114224A1 (en)	2021-12-13	2023-06-22	Sage Therapeutics, Inc.	Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2594323A (en)	1948-07-22	1952-04-29	Upjohn Co	24-substituted delta 5-cholene-3, 24-diols
US2673206A (en) *	1950-06-07	1954-03-23	Schering Corp	25-ethinyl steroids
US3079385A (en)	1961-01-24	1963-02-26	Roussel Uclaf	Novel process of preparation of polyhydroxylated pregnanes
US3206459A (en)	1962-10-19	1965-09-14	Syntex Corp	10alpha-pregnan-19-ol derivatives
JPS5324071B2 (2) *	1974-04-30	1978-07-18
US4071625A (en)	1974-05-13	1978-01-31	Richardson-Merrell Inc.	19-Oxygenated-5α-androstanes for the enhancement of libido
CH628907A5 (en) *	1975-10-10	1982-03-31	Hoffmann La Roche	Process for the preparation of 24,25-dihydroxycholesterol derivatives
JPS5840960B2 (ja) *	1976-12-28	1983-09-08	帝人株式会社	ヒドロキシコレステロ−ル立体異性体間の相互変換法
US4183852A (en) *	1977-07-18	1980-01-15	Kaiser Emil T	Process for preparing 25-hydroxycholesterol
JPS54163565A (en) *	1978-06-09	1979-12-26	Teijin Ltd	24255epoxyy3beta 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production
US4174345A (en) *	1978-08-01	1979-11-13	Kaiser Emil T	Synthesis of steroids
US4269777A (en) *	1979-05-21	1981-05-26	Wisconsin Alumni Research Foundation	Isotopically labeled vitamin D derivatives and processes for preparing same
JPS5735597A (en) *	1980-08-13	1982-02-26	Teijin Ltd	25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation
JPS61254599A (ja) *	1985-05-07	1986-11-12	Sumitomo Pharmaceut Co Ltd	コレステロ−ルのフツ素誘導体
ATE45347T1 (de) *	1985-05-30	1989-08-15	Taisho Pharmaceutical Co Ltd	Vitamin d3-derivate.
JPS62187485A (ja) *	1986-02-13	1987-08-15	Teijin Ltd	２４，２５−エポキシコレステロ−ル類の製造法
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU698834B2 (en)	1993-05-24	1998-11-12	Purdue Pharma Ltd.	Methods and compositions for inducing sleep
IL110309A0 (en)	1993-07-15	1994-10-21	Univ Kentucky Res Found	A method of protecting against neuron loss
KR100338287B1 (ko)	1994-02-14	2002-11-30	푸르듀 파머 리미티드	감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US5595996A (en)	1994-10-25	1997-01-21	Merck & Co., Inc.	7-substituted 4-aza cholanic acid derivatives and their use
JPH08268917A (ja)	1995-03-31	1996-10-15	D D S Kenkyusho:Kk	癌組織への移行性の高い制癌剤
RU2194712C2 (ru)	1995-06-06	2002-12-20	Коукенсис, Инк.	НЕЙРОАКТИВНЫЕ СТЕРОИДЫ, ФАРМАЦЕВТИЧЕСКИЙ ПРЕПАРАТ, СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАЗЛИЧНЫХ НАРУШЕНИЙ, СПОСОБ ИНДУКЦИИ СНА И СПОСОБ ИНДУКЦИИ АНЕСТЕЗИИ С ИХ ИСПОЛЬЗОВАНИЕМ, СПОСОБ МОДУЛИРОВАНИЯ КОМПЛЕКСА РЕЦЕПТОР ГАМКa-ХЛОРИДНЫЙ ИОНОФОР
US6645953B2 (en)	1995-06-23	2003-11-11	Novo Nordisk A/S	Meiosis regulating compounds
IL122609A0 (en)	1995-06-23	1998-08-16	Novo Nordisk As	Meiosis regulating compounds
US5888996A (en)	1995-07-26	1999-03-30	Trustees Of Boston University	Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
AU3068497A (en) *	1996-05-06	1997-11-26	Bionumerik Pharmaceuticals, Inc.	Process for preparing 27-hydroxy cholesterol and related derivatives
JPH09328498A (ja) *	1996-06-10	1997-12-22	Teijin Ltd	２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体
US6122371A (en)	1997-07-22	2000-09-19	Atwell; Ronald C.	Apparatus for protecting coin-operated telephones from vandalism and larceny
KR20010043558A (ko)	1998-05-13	2001-05-25	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	감수분열 조절 화합물
US8541600B2 (en) *	1998-11-24	2013-09-24	Harbor Therapeutics, Inc.	11-aza, 11-thia and 11-oxa sterol compounds and compositions
GB9910934D0 (en)	1999-05-11	1999-07-14	Res Inst Medicine Chem	Chemical compounds
CN1111167C (zh) *	1999-10-22	2003-06-11	中国科学院上海有机化学研究所	3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途
GB0000228D0 (en)	2000-01-06	2000-03-01	Phytopharm Plc	Fluoro substituted sapogenins and their use
GB0019290D0 (en)	2000-08-04	2000-09-27	Symphar Sa	Methods for inducing apolipoprotein E secretion
GR1003861B (el)	2000-12-29	2002-04-11		Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
GB0107822D0 (en)	2001-03-28	2001-05-23	Phytopharm Plc	Sapogenin derivatives their synthesis and use methods based upon their use
US20070197484A1 (en)	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
CA2466033A1 (en)	2001-11-08	2003-05-15	The University Of Chicago	Method of treating disorder related to high cholesterol concentration
JP2005511713A (ja)	2001-12-07	2005-04-28	ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア	加齢性黄斑変性についての処置
PL213697B1 (pl)	2002-03-27	2013-04-30	Phytopharm Plc	Substancje czynne do stosowania w leczeniu chorób, zwlaszcza chorób neurodegeneracyjnych
KR101130212B1 (ko)	2002-03-27	2012-04-13	파이토팜 피엘씨	사포게닌 및 그 유도체의 치료 방법 및 사용법
WO2004055201A2 (en)	2002-12-13	2004-07-01	Bayer Healthcare Ag	Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
FR2850023B1 (fr)	2003-01-17	2007-04-06	Mapreg	Medicaments pour le systeme nerveux
GB0403889D0 (en)	2004-02-21	2004-03-24	Univ Edinburgh	Uses of er-beta modulators
WO2006037016A2 (en)	2004-09-27	2006-04-06	The Regents Of The University Of California	Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
US9670244B2 (en)	2006-02-27	2017-06-06	The Regents Of The University Of California	Oxysterol compounds and the hedgehog pathway
US8273747B2 (en)	2006-11-02	2012-09-25	Curis, Inc.	Small organic molecule regulators of cell proliferation
JP5587184B2 (ja)	2007-06-20	2014-09-10	オースペックス・ファーマシューティカルズ・インコーポレイテッド	繊維症阻害剤としての置換ｎ−アリールピリジノン
EP2207542A2 (en)	2007-11-06	2010-07-21	N.V. Organon	A method of hormone suppression in humans
WO2009090063A1 (en)	2008-01-16	2009-07-23	Jado Technologies Gmbh	Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
NZ589764A (en) *	2008-05-09	2012-10-26	Univ Emory	NMDA receptor antagonists for the treatment of neuropsychiatric disorders
WO2010065709A2 (en)	2008-12-03	2010-06-10	Amin Khan	Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20120040916A1 (en)	2008-12-22	2012-02-16	Massachusetts Institute Of Technology	Molecular inhibitors of the wnt/beta-catenin pathway
US20110319416A1 (en)	2009-01-28	2011-12-29	Emory University	Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
EP2459581A4 (en)	2009-07-29	2012-12-26	Univ Chicago	LIVER X-RECEPTOR AGONISTS
WO2011028794A2 (en)	2009-09-01	2011-03-10	Lazarus Therapeutics, Inc.	Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
FR2953138B1 (fr)	2009-12-02	2015-10-16	Assist Publ Hopitaux Marseille	Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus
CA2784119A1 (en) *	2009-12-15	2011-06-23	Neurop, Inc.	Compounds for the treatment of neurologic disorders
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
US20120035156A1 (en)	2010-08-09	2012-02-09	Daniela Alberati	Combination of glyt1 compound with antipsychotics
US8969525B2 (en)	2010-11-09	2015-03-03	Enzo Life Sciences, Inc.	Hydroxycholesterol immunoassay
WO2012142039A1 (en)	2011-04-15	2012-10-18	University Of North Dakota	Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases
EP2714081A4 (en)	2011-05-27	2015-09-09	Cytocure Llc	METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT
JP2014521662A (ja)	2011-07-29	2014-08-28	ザリージェンツオブザユニバーシティオブカリフォルニア	ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド
HRP20230747T1 (hr)	2011-09-08	2024-01-05	Sage Therapeutics, Inc.	Neuroaktivni steroidi, pripravci i njihova uporaba
CN119192266A (zh) *	2011-10-14	2024-12-27	萨奇治疗股份有限公司	3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2013163455A2 (en)	2012-04-25	2013-10-31	The Regents Of The University Of California	A drug screening platform for rett syndrome
US20140149272A1 (en)	2012-08-17	2014-05-29	Trueex Group Llc	Interoffice bank offered rate financial product and implementation
MX365644B (es)	2012-12-18	2019-06-10	Univ Washington	Esteroides neuroactivos sustituidos con 19-alcoxi-17, profarmacos de los mismos, y metodos de tratamiento usando los mismos.
WO2014115167A2 (en)	2013-01-23	2014-07-31	Sphaera Pharma Pvt. Ltd.	Novel compounds of 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
KR20150110787A (ko)	2013-01-29	2015-10-02	노렉스, 인크.	스피로-락탐 nmda 수용체 조절인자 및 그의 용도
SMT201800657T1 (it)	2013-03-13	2019-01-11	Sage Therapeutics Inc	Steroidi neuroattivi e loro metodi di utilizzo
CN105164161A (zh)	2013-03-13	2015-12-16	萨奇治疗股份有限公司	神经活性类固醇、组合物、及其用途
WO2015195967A1 (en)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
US10238664B2 (en)	2014-07-09	2019-03-26	Duke University	Compositions and methods for the repair of myelin
US10016095B2 (en) *	2014-10-03	2018-07-10	Progressive International Corporation	Salad spinner
SG11201702799UA (en) *	2014-10-07	2017-05-30	Sage Therapeutics Inc	Neuroactive compounds and methods of use thereof
PL3319611T3 (pl)	2015-07-06	2021-07-12	Sage Therapeutics, Inc.	Oksysterole i sposoby ich stosowania
MX382122B (es)	2015-07-06	2025-03-13	Sage Therapeutics Inc	Oxiesteroles y metodos de uso de los mismos.
AU2016289965B2 (en)	2015-07-06	2021-09-09	Sage Therapeutics, Inc.	Oxysterols and methods of use thereof
GB2557875A (en)	2015-09-02	2018-07-04	Univ Swansea	Diagnostic methods and kits
US11969506B2 (en)	2017-03-15	2024-04-30	Modernatx, Inc.	Lipid nanoparticle formulation
BR112019027458A2 (pt)	2017-06-23	2020-07-07	Intercept Pharmaceuticals, Inc.	métodos e intermediários para a preparação de derivados de ácidos biliares
AU2018364659A1 (en)	2017-11-10	2020-05-28	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in treating genetic epileptic disoders

2016
- 2016-07-06 AU AU2016289965A patent/AU2016289965B2/en active Active
- 2016-07-06 JP JP2017568208A patent/JP6882996B2/ja active Active
- 2016-07-06 CA CA2991311A patent/CA2991311C/en active Active
- 2016-07-06 HK HK18114684.2A patent/HK1255500A1/zh unknown
- 2016-07-06 EP EP23199636.4A patent/EP4316591A3/en active Pending
- 2016-07-06 EP EP16821920.2A patent/EP3319610A4/en not_active Withdrawn
- 2016-07-06 US US15/742,422 patent/US10696712B2/en active Active
- 2016-07-06 WO PCT/US2016/041160 patent/WO2017007832A1/en not_active Ceased
- 2016-07-06 MA MA042409A patent/MA42409A/fr unknown
2020
- 2020-05-20 US US16/879,460 patent/US20210101925A1/en not_active Abandoned
2021
- 2021-01-07 JP JP2021001453A patent/JP7410062B2/ja active Active
- 2021-08-20 AU AU2021218227A patent/AU2021218227B2/en active Active
2022
- 2022-05-20 US US17/749,976 patent/US20230047157A1/en not_active Abandoned
- 2022-07-01 JP JP2022107293A patent/JP7478190B2/ja active Active
2024
- 2024-06-18 US US18/746,388 patent/US20250154192A1/en active Pending

Publication	Publication Date	Title
JP2018519329A5 (2)	2019-07-25
JP2018519328A5 (2)	2019-07-25
JP2018519351A5 (2)	2019-07-25
JP2019519587A5 (2)	2020-08-13
JP2017518323A5 (2)	2018-07-26
JP2019532078A5 (2)	2020-11-26
JP2015512951A5 (2)	2016-06-09
RU2018104278A (ru)	2019-08-06	Оксистеролы и способы их применения
JP2019532079A5 (2)	2020-11-26
HRP20211282T1 (hr)	2021-11-12	Oksisteroli i postupci njihovog korištenja
JP2013032389A5 (2)	2013-03-28
JP2015508092A5 (2)	2015-10-15
JP2017531020A5 (2)	2018-11-29
JP2016512531A5 (2)	2019-01-31
JP2015517555A5 (2)	2016-07-14
JP2016513663A5 (2)	2017-04-13
JP2009531277A5 (2)	2012-07-26
JP2015181191A5 (2)	2016-07-21
JP2016503793A5 (2)	2017-02-02
JP2010095546A5 (2)	2010-12-24
RU2019115113A (ru)	2020-11-24	Оксистеролы и способы их применения
JP2013505929A5 (2)	2013-11-07
JP2014500861A5 (2)	2014-12-11
JP2014051526A5 (2)	2014-08-14
JP2012502111A5 (2)	2012-10-25